Alex Cartana

10x Wins Injunction From Unified Patent Court Banning Sales of NanoString's CosMx Products in Europe

Retrieved on: 
Tuesday, September 19, 2023
Patent, NanoString Technologies, Genomics, Federal Patent Court (Germany), 10x Genomics, SMI, UPC, Palatine Higher Regional Court, Research, RNA, Science, Invention, Rosenbergia xenium, District court, Investment, Patient, European, Unified Patent Court, European Patent Convention, Court, Health, Douglas v. U.S. District Court ex rel Talk America, Disease, Alex Cartana, Microscope

PLEASANTON, Calif., Sept. 19, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") issued a preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG) for infringing European Patent 4 108 782 B1 ("the EP 782 patent," docket No 459746/2023). The preliminary injunction, issued by a panel of four judges with both legal and technical expertise, prevents NanoString from selling or providing services using its CosMx Spatial Molecular Imager (SMI) instruments and CosMx reagents for RNA detection in all 17 countries of the UPC.

Key Points: 
  • "A patent holder must meet a very high standard to win a preliminary injunction," added Whitaker.
  • "Two separate courts have now found that NanoString's CosMx products infringe two different 10x patents, and three separate courts have preliminarily found the 10x patents valid in the asserted scope.
  • The full opinions of the Unified Patent Court will be posted here when available: 10xgen.com/munich-spatial-news .
  • 10x also intends to seek an injunction against sales of GeoMx as well as ongoing damages.

10x Genomics Wins Permanent Injunction Against NanoString's CosMx Products

Retrieved on: 
Wednesday, May 17, 2023
Tissue, Patent, NanoString Technologies, Genomics, Federal Patent Court (Germany), Pathology, SMI, Software, Research, Gene expression, Cell, RNA, H&E, Invention, Chemistry, District court, Data analysis, 10x Genomics, Risk, Hearing, European Patent Convention, SNV, Biology, Douglas v. U.S. District Court ex rel Talk America, Gene, Alex Cartana, Tobacco, Generic drug, Antibiotics, Medical imaging, Vaccine, Microscope, Rosenbergia xenium

PLEASANTON, Calif., May 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has won an injunction in its patent litigation against NanoString Technologies, Inc. (Nasdaq: NSTG) and NanoString Technologies Germany GmbH.

Key Points: 
  • The Munich Regional Court issued the injunction based on its finding that the CosMx products infringe European Patent Number 2794928B1, which relates to in situ detection of analytes.
  • "10x has invested more than $1 billion in cutting edge research and development, resulting in many breakthrough products and more than 800 patents, including foundational intellectual property for our in situ products," said Eric S. Whitaker, Chief Legal Officer of 10x Genomics.
  • We have already requested an injunction against NanoString's infringing CosMx products in the United States and expect to seek other injunctions where NanoString's infringing CosMx products are sold."
  • The injunction will be provisionally enforced by 10x Genomics after providing a security bond in the amount of 3.5 million Euros and includes any CosMx reagents for RNA detection as well as the use of CosMx Spatial Molecular Imager (CosMx SMI) instruments.

Spatial Omics Solutions Market worth $587.2 Million by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, August 10, 2022
Laboratory, Genome, NanoString Technologies, Prevalence, Research, OMICS, Fluorescence, Proteomics, NGS, RNA, ABS, Illumina, Inc., Biology, Genomics, US, Development, Machine learning, MMI, Gene, Cell biology, Technology, Alex Cartana, MIF, DNA, Translational research, CAGR, Diagnosis, RC2, Seminal vesicles, Drug discovery, Income, 10x Genomics, Lists of diseases, Virology, Drug development, AstraZeneca, Miltenyi Biotec, Biomarker, EV, Bruker, Neuroscience, Analysis, Malignancy, Renewable energy, Medical imaging, Microscope, Akoya

According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.
  • The phrase "spatial omics" refers to a group of technologies that allow -omics data to be superimposed on images of tissue.
  • There are several different types of omics studies that are all grouped under the umbrella word "omics."
  • Global Spatial Omics Solutions Market, by Solution Type, 2022-2030 (Value US$ Mn)

Spatial Omics Solutions Market worth $587.2 Million by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, August 10, 2022
Laboratory, Genome, NanoString Technologies, Prevalence, Research, OMICS, Fluorescence, Proteomics, NGS, RNA, ABS, Illumina, Inc., Biology, Genomics, US, Development, Machine learning, MMI, Gene, Cell biology, Technology, Alex Cartana, MIF, DNA, Translational research, CAGR, Diagnosis, RC2, Seminal vesicles, Drug discovery, Income, 10x Genomics, Lists of diseases, Virology, Drug development, AstraZeneca, Miltenyi Biotec, Biomarker, EV, Bruker, Neuroscience, Analysis, Malignancy, Renewable energy, Medical imaging, Microscope, Akoya

According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.
  • The phrase "spatial omics" refers to a group of technologies that allow -omics data to be superimposed on images of tissue.
  • There are several different types of omics studies that are all grouped under the umbrella word "omics."
  • Global Spatial Omics Solutions Market, by Solution Type, 2022-2030 (Value US$ Mn)

RNA Analysis/Transcriptomics Global Market Research Report 2022: Microarrays, Sequencing, PCR, RNA Interference, Clinical Diagnostics, Drug Discovery, Toxicogenomics, Comparative Transcriptomics - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 8, 2022
Software, Technology, Health, Medical Devices, Sigma-Aldrich, NGS, US, Technology, Illumina, Inc., Personalized medicine, Transcriptome, Thermo Fisher Scientific, 10x Genomics, RNA-Seq, Software, RNA, RNA interference, Environment, Organization, US FDA, Library, Growth, Agilent Technologies, Acquisition, Diagnosis, Drug discovery, GE Healthcare, Application, PMC, Genomics, Medicinal plants, Vaccine, Dietary supplement, Illumina, Alex Cartana

The RNA analysis/ transcriptomics market consists of sales of RNA analysis products and related services by entities (organizations, sole traders, and partnerships) that provide RNA analysis.

Key Points: 
  • The RNA analysis/ transcriptomics market consists of sales of RNA analysis products and related services by entities (organizations, sole traders, and partnerships) that provide RNA analysis.
  • Technological advancements and innovations in RNA analysis are emerging trends in the RNA analysis/ transcriptomics market.
  • Global RNA Analysis/ Transcriptomics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    6.3.
  • Global RNA Analysis/ Transcriptomics Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

10x Genomics Advances Leadership and Innovation in Single Cell and Spatial Technologies at 2022 AGBT General Meeting

Retrieved on: 
Tuesday, June 7, 2022
Fixed, Vexillum xenium, Result, Cohort study, Publication, COVID-19, Medicine, History, Tissue, Disclosure, U.S. Securities and Exchange Commission, Histology, Forward-looking statement, Software, Alex Cartana, Conversation, B cell, Mass meeting, Health, Securities Exchange Act of 1934, Social media, Securities Act of 1933, Nature, Spatial analysis, Genomics, Neuroscience, Biology, Archive, Patent, RNA, Financial condition report, Security (finance), Risk, Analysis, Regulation Fair Disclosure, Single-cell analysis, Private Securities Litigation Reform Act, Chromium, Leadership, Research, 10x Genomics, Disease, Nasdaq, Investment, Regulation, Workflow, Adoption, Protein, General officer, Terminology, Oil, Microscope, Mobile phone, Vaccine, Pharmaceutical industry, Technology, Visium Asset Management

We look forward to demonstrating the power of 10x Genomics' leading platforms, showcasing researchers' success with our technologies and highlighting our robust product pipeline at AGBT."

Key Points: 
  • We look forward to demonstrating the power of 10x Genomics' leading platforms, showcasing researchers' success with our technologies and highlighting our robust product pipeline at AGBT."
  • 10x Genomics today announced the compatibility of its recently launched Fixed RNA Profiling Kit to enable single-cell transcriptomics on dissociated formalin-fixed, paraffin-embedded (FFPE) tissues.
  • Building on its leadership and innovation in single-cell and spatial analysis, 10x Genomics is planning to launch its Xenium platform for in situ analysis later this year.
  • 10x Genomics will present five posters during AGBT demonstrating the use of its platforms to generate novel biological insights.